AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors
Executive Summary
Confusion over top-line pooled cardiovascular Phase III safety data on anemia therapy roxadustat caused shares in AstraZeneca and FibroGen to slide on 9 May, but analysts later said the negative reaction was overdone.
You may also be interested in...
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
AZ On The Rise In All Regions And Therapy Areas
The drug major's Q2 sales soared past consensus forecasts, driven by its three soon-to-be oncology blockbusters – Tagrisso, Imfinzi and Lynparza.
AZ's Farxiga Fillip As Drug Reduces Renal Disease Risk In Type 2 Diabetics
AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in its battles with Jardiance and Invokana.